Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acarbose versus placebo for endothelial function in coronary artery disease with impaired glucose tolerance or newly diagnosed diabetes
2004-002579-17Phase 4Active
- Sponsor
- Medizinische Klinik B
- Start
- Jun 2006
- Modality
- Microbiome-Derived Products → Microbiome Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in prediabetes, diabetes mellitus (DM) and coronary arteriosclerosis comparing Glucobay with Placebo (2 arms). Primary endpoint: Improvement in endothelial-dependent vasodilation. Started Jun 2006; status: active.
02
Drugs
acarbose
03
Conditions
prediabetesdiabetes mellitus (DM)coronary arteriosclerosis
Beyond the preview
Go deeper on 2004-002579-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002579-17.